Early Support in Primary Care for People Starting Treatment for Cancer (GI-ACP)
Primary Purpose
Cancer of Pancreas, Cancer of Stomach, Cancer of Esophagus
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Anticipatory care planning letter
Sponsored by
About this trial
This is an interventional supportive care trial for Cancer of Pancreas focused on measuring Oncology, Palliative Care, Primary care, Care planning
Eligibility Criteria
Inclusion Criteria:
- People with advanced, inoperable oesophageal, gastric or pancreatic cancers
- People being offered palliative chemotherapy and/or radiotherapy
Exclusion Criteria:
- People too ill to participate or give informed consent.
- Patient who are not fit for oncology treatment or who opt for best supportive care.
- People with other life-limiting conditions likely to cause death within 6 months.
- People with moderate to severe cognitive impairment that precludes completions of questionnaires or participation in interviews.
- People unable to give informed consent or communicate by telephone with the researcher.
Sites / Locations
- Royal Infirmary of Edinburgh, NHS Lothian
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Early support group
Usual care group
Arm Description
This group receive the Anticipatory care planning letter to take to their GP and the GP receives a copy of the Scottish Anticipatory Care Planning information leaflet and a short communication guide about ACP.
No change to standard care from oncology services and primary care
Outcomes
Primary Outcome Measures
Health related quality of life: EuroQol EQ-5D-5L
Health related quality of life assessed using the EuroQol EQ-5D-5L.
The EQ-5D-5L has 2 components:
There is a descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.
The EQ VAS (visual analogue scale) records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'.
The users guide gives details of the scoring system: https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-5L_UserGuide_2015.pdf
Secondary Outcome Measures
Trial feasibility assessment: conversion rate
Screening to consent conversion rate
Full Information
NCT ID
NCT03719716
First Posted
September 17, 2018
Last Updated
March 8, 2021
Sponsor
NHS Lothian
Collaborators
NHS Fife
1. Study Identification
Unique Protocol Identification Number
NCT03719716
Brief Title
Early Support in Primary Care for People Starting Treatment for Cancer
Acronym
GI-ACP
Official Title
Early Support in Primary Care for People Starting Treatment for Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
January 1, 2019 (Actual)
Primary Completion Date
August 31, 2020 (Actual)
Study Completion Date
December 31, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NHS Lothian
Collaborators
NHS Fife
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a feasibility, randomised controlled trial (RCT) of a person-centred care planning intervention involving patients recently diagnosed with a poor prognosis cancer who are starting a palliative oncology treatment in a Scottish regional cancer centre.
Detailed Description
This study will evaluate the feasibility and acceptability of an early 'palliative care' intervention consisting of anticipatory care planning coordinated in primary care that is systematically triggered when patients with poor prognosis gastrointestinal cancers start palliative oncology treatment.
Patients will be identified and invited to participate during their assessment and treatment planning by the cancer care clinicians. A screening log will record eligible cases. Patients who consent will be randomised to receive a letter about the benefits of early anticipatory care planning to take to their preferred general practitioner to help trigger earlier support by their primary care team. Control patients receive usual care. All study patients will be asked to complete 3 questionnaires (EuroQol EQ-5D-5L (full title of tool), ICECAP Supportive Care Measure (full title of tool), and CollaboRATE (full title of tool) for shared decision-making) at baseline, 6, 12, 24 and 48 weeks. A purposive sub-sample of patients, family carer and general practitioner (GP) triads will be invited for interview at around 6 and 20 weeks to explore their experiences of trial participation, their illness and care. Health service use will be recorded including hospital admissions, oncology treatment, palliative care referral, time and place of death or survivorship.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer of Pancreas, Cancer of Stomach, Cancer of Esophagus
Keywords
Oncology, Palliative Care, Primary care, Care planning
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Feasibility randomised controlled trial
Masking
ParticipantOutcomes Assessor
Masking Description
Participants will be randomised automatically by the local trials unit and allocated a study number. This will be used in all statistical analyses and other quantitative data analysis including the questionnaires. The study researcher will know the identity of the participants she interviews and the qualitative analysis cannot be blinded although all data generated will be anonymised.
Allocation
Randomized
Enrollment
46 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Early support group
Arm Type
Experimental
Arm Description
This group receive the Anticipatory care planning letter to take to their GP and the GP receives a copy of the Scottish Anticipatory Care Planning information leaflet and a short communication guide about ACP.
Arm Title
Usual care group
Arm Type
No Intervention
Arm Description
No change to standard care from oncology services and primary care
Intervention Type
Other
Intervention Name(s)
Anticipatory care planning letter
Intervention Description
Patient letter to take to GP and GP literature
Primary Outcome Measure Information:
Title
Health related quality of life: EuroQol EQ-5D-5L
Description
Health related quality of life assessed using the EuroQol EQ-5D-5L.
The EQ-5D-5L has 2 components:
There is a descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.
The EQ VAS (visual analogue scale) records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'.
The users guide gives details of the scoring system: https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-5L_UserGuide_2015.pdf
Time Frame
Baseline to 48 weeks or death
Secondary Outcome Measure Information:
Title
Trial feasibility assessment: conversion rate
Description
Screening to consent conversion rate
Time Frame
Baseline to 48 weeks or death for last recruited participant
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
People with advanced, inoperable oesophageal, gastric or pancreatic cancers
People being offered palliative chemotherapy and/or radiotherapy
Exclusion Criteria:
People too ill to participate or give informed consent.
Patient who are not fit for oncology treatment or who opt for best supportive care.
People with other life-limiting conditions likely to cause death within 6 months.
People with moderate to severe cognitive impairment that precludes completions of questionnaires or participation in interviews.
People unable to give informed consent or communicate by telephone with the researcher.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kirsty Boyd, PhD
Organizational Affiliation
The University of Edinburgh/ NHS Lothian
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royal Infirmary of Edinburgh, NHS Lothian
City
Edinburgh
State/Province
Midlothian
ZIP/Postal Code
EH164SA
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
All non-person identifiable data will be collected and stored to allow it to be archived and shared
IPD Sharing Time Frame
Up to 10 years post study
IPD Sharing Access Criteria
During study data will not be shared just the supporting information. After study storage will be arranged by The University of Edinburgh
Learn more about this trial
Early Support in Primary Care for People Starting Treatment for Cancer
We'll reach out to this number within 24 hrs